Thus far, data from frontline trials using CPIs in lung cancer would justifyprescription of pembrolizumab to patients with at least 50% tumor cells positivefor PD-L1 staining; and chemotherapy for those who are do not show this level ofstaining. This evidence concerns the gene CD274 and lung carcinoma.